<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529785</url>
  </required_header>
  <id_info>
    <org_study_id>2700</org_study_id>
    <nct_id>NCT04529785</nct_id>
  </id_info>
  <brief_title>Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation</brief_title>
  <acronym>VEIN-AF</acronym>
  <official_title>Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable Pulmonary Vein Isolation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ Sint-Jan AV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The superior vena cava (SVC) is one of the most common non pulmonary vein (PV)-triggers for&#xD;
      atrial tachyarrhythmias. SVC electrical isolation can be reached by circular radiofrequency&#xD;
      (RF)-ablation under close monitoring of the phrenic nerve. However, adding substrate&#xD;
      modification and vein of Marshal (VoM) ethanol infusion to the ablation procedure might&#xD;
      substantially improve long-term outcomes.&#xD;
&#xD;
      The aim of this study is to evaluate the recurrence rate 1 year after the index ablation in&#xD;
      patients undergoing a redo ablation for recurrent paroxysmal atrial fibrillation (PAF)&#xD;
      despite durable pulmonary vein isolation (PVI) with either SVC isolation alone or with&#xD;
      substrate modification including vein of Marshal ethanolisation in addition to SVC isolation&#xD;
      alone&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of atrial tachyarrhythmia 1 year after the index ablation</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the prevalence of atrial tachyarrhythmia recurrence 1 year after the index ablation between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety (complications)</measure>
    <time_frame>During procedure</time_frame>
    <description>Comparison of the number of procedural complications between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total procedural time</measure>
    <time_frame>During procedure</time_frame>
    <description>Comparison of the procedural time between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>During procedure</time_frame>
    <description>Comparison of the fluoroscopy time between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RF ablation time</measure>
    <time_frame>During procedure</time_frame>
    <description>Comparison of the radiofrequency time between groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>SVC only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in Group 1 will receive an SVC isolation only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SVC isolation with substrate modification and VoM inf</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in Group 2 will receive an SVC isolation with substrate modification and vein of Marshal ethanol infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SVC only</intervention_name>
    <description>Patients allocated to this arm will receive an RF ablation with the isolation of the SVC alone</description>
    <arm_group_label>SVC only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SVC isolation with substrate modification and vein of Marshal ethanol infusion</intervention_name>
    <description>Patients allocated to this arm will receive an RF ablation with the isolation of the SVC, substrate modification and vein of Marshal ethanol infusion</description>
    <arm_group_label>SVC isolation with substrate modification and VoM inf</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years&#xD;
&#xD;
          -  Patients scheduled for a repeat ablation of PAF after a previous PVI&#xD;
&#xD;
          -  Confirmation of lasting pulmonary vein isolation at the time of randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with persistent atrial fibrillation&#xD;
&#xD;
          -  Previous ablation with isolation of the SVC, roofline, mitral line or previous vein of&#xD;
             Marshal ethanol infusion&#xD;
&#xD;
          -  Left atrial thrombus. Left atrial appendage thrombus can be determined by&#xD;
             preprocedural imaging: CT, transesophageal echocardiography or MRI.&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;35%.&#xD;
&#xD;
          -  Cardiac surgery within the previous 90 days.&#xD;
&#xD;
          -  Expecting cardiac transplantation or other cardiac surgery within 180 days.&#xD;
&#xD;
          -  Coronary percutaneous transluminal coronary angioplasty/stenting within the previous&#xD;
             90 days or myocardial infarction within the previous 60 days.&#xD;
&#xD;
          -  Documented history of a thromboembolic event within the previous 90 days.&#xD;
&#xD;
          -  Diagnosed atrial myxoma.&#xD;
&#xD;
          -  Significant restrictive, constrictive, or chronic obstructive pulmonary disease with&#xD;
             chronic symptoms.&#xD;
&#xD;
          -  Significant congenital anomaly or medical problem that in the opinion of the&#xD;
             investigator would preclude enrollment&#xD;
&#xD;
          -  Women who are pregnant or who plan to become pregnant during the study.&#xD;
&#xD;
          -  Acute illness or active infection at time of index procedure&#xD;
&#xD;
          -  Advanced renal insufficiency&#xD;
&#xD;
          -  Unstable angina.&#xD;
&#xD;
          -  History of blood clotting or bleeding abnormalities.&#xD;
&#xD;
          -  Contraindication to anticoagulation.&#xD;
&#xD;
          -  Life expectancy less than 1 year.&#xD;
&#xD;
          -  Presence of a condition that precludes vascular access.&#xD;
&#xD;
          -  International Normalized Ratio greater than 3.5 within 24 hours of procedure - for&#xD;
             patients taking warfarin.&#xD;
&#xD;
          -  Patient cannot be removed from antiarrhythmic drugs for reasons other than AF.&#xD;
&#xD;
          -  Unwilling or unable to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SÃ©bastien Knecht, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Sint-Jan AV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Lycke, MSc, PhD</last_name>
    <phone>+32 50 45 32 93</phone>
    <email>michelle.lycke@azsintjan.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge-Oostende AV</name>
      <address>
        <city>Brugge</city>
        <state>Please Select</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Lycke, MSc, PhD</last_name>
      <phone>00 32 45 32 93</phone>
      <email>michelle.lycke@azsintjan.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Sint-Jan AV</investigator_affiliation>
    <investigator_full_name>Sebastien Knecht</investigator_full_name>
    <investigator_title>Professor Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

